A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)

被引：0

作者：

Markman, B. ^{[1
]}

Solomon, B. ^{[2
]}

Nott, L. M. ^{[3
]}

Roberts-Thomson, R. ^{[4
]}

Hughes, B. ^{[5
]}

Pavlakis, N. ^{[6
]}

Davis, A. ^{[7
]}

Brown, L. J. ^{[8
]}

Parakh, S. ^{[9
]}

Brungs, D. ^{[10
]}

Bowyer, S. E. ^{[11
]}

Nordman, I. ^{[12
]}

Jennens, R. ^{[13
]}

Warburton, L. ^{[14
]}

Harris, S. J. ^{[15
]}

Samuel, E. ^{[16
]}

Ramanujam, S. ^{[17
]}

Wang, A. ^{[18
]}

Dumas, M. ^{[19
]}

Gard, G. ^{[19
]}

机构：

[1] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia

[2] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[3] Royal Hobart Hosp, Dept Med Oncol, Hobart, Tas, Australia

[4] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia

[5] Prince Charles Hosp, Canc Care Serv, Chermside, Qld, Australia

[6] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia

[7] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[8] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[9] Olivia Newton John Canc Res Inst, Med Oncol Dept, Heidelberg, Vic, Australia

[10] Wollongong Hosp, Dept Med Oncol, Illawarra Canc Ctr, Wollongong, NSW, Australia

[11] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia

[12] Calvary Mater Hosp Newcastle, Dept Med Oncol, Newcastle, NSW, Australia

[13] Peter MacCallum Canc Ctr, Med Oncol, East Melbourne, Vic, Australia

[14] Fiona Stanley Hosp, Dept Med Oncol, Perth, WA, Australia

[15] Bendigo Hlth, Ctr Canc, Bendigo, Vic, Australia

[16] Latrobe Reg Hosp, Med Oncol, Traralgon, Vic, Australia

[17] Griffith Base Hosp, Dept Med Oncol, Griffith, NSW, Australia

[18] Amgen Inc, CfOR, Sydney, NSW, Australia

[19] Walter & Eliza Hall Inst Med Res, Dept Oncol, Parkville, Vic, Australia

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.668

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

590P

引用

页码：S1700 / S1700

页数：1

共 50 条

[31] Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
Sacher, A.
Patel, M. R.
Miller, W. H., Jr.
Desai, J.
Garralda, E.
Bowyer, S.
Kim, T. W.
De Miguel, M.
Falcon, A.
Krebs, M. G.
Lee, J.
Cheng, M.
Han, S. -W.
Shacham-Shmueli, E.
Forster, M.
Jerusalem, G.
Massarelli, E.
Paz-Ares Rodriguez, L.
Prenen, H.
Walpole, I.
Arbour, K.
Choi, Y.
Dharia, N. V.
Lin, M.
Mandlekar, S.
Joo, S. Royer
Shi, Z.
Schutzman, J.
LoRusso, P.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S8 - S9
[32] Real World Efficacy and Safety of Sotorasib in US Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Zhou, K. I.
Lin, C.
Tseng, C. -L.
Ramnath, N.
Dowell, J. E.
Kelley, M. J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S337 - S338
[33] Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
Lu, S.
Jian, H.
Zhang, Y.
Song, Z.
Zhao, Y.
Wang, P.
Jiang, L.
Gong, Y.
Zhou, J.
Dong, X.
Yang, N.
Fang, J.
Zhuang, W.
Cang, S.
Ma, R.
Shi, J.
Wu, P.
Lu, J.
Xiang, Z.
Shi, Z.
Zhang, L.
Wang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S11 - S11
[34] Early-stage KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Australia.
Mitchell, Paul
Dharmaraj, Devisri
Knight, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[35] KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
Rosell, Rafael
Codony-Servat, Jordi
Gonzalez, Jessica
Santarpia, Mariacarmela
Jain, Anisha
Shivamallu, Chandan
Wang, Yu
Gimenez-Capitan, Ana
Molina-Vila, Miguel A.
Nilsson, Jonas
Gonzalez-Cao, Maria
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
[36] Characteristics and Treatment Sequences of Patients with KRAS G12C, Other KRAS and KRAS-Wild-Type Advanced or Metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME Cohort
Girard, Nicolas
Perol, Maurice
Debieuvre, Didier
Lemonnier, Lydie
Veillard, Charlotte
Caillon, Megane
Tzala, Lia
Desamericq, Gaelle
Audigier-Valette, Clarisse
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 342 - 342
[37] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Tereza Vaclova
Atanu Chakraborty
James Sherwood
Sarah Ross
Danielle Carroll
J. Carl Barrett
Julian Downward
Elza C. de Bruin
Scientific Reports, 12
[38] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Lee, Arnold
TARGETED ONCOLOGY, 2022, 17 (06) : 727 - 733
[39] Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer
Arbour, Kathryn C.
Rizvi, Hira
Plodkowski, Andrew J.
Hellmann, Matthew D.
Knezevic, Andrea
Heller, Glenn
Yu, Helena A.
Ladanyi, Marc
Kris, Mark G.
Arcila, Maria E.
Rudin, Charles M.
Lito, Piro
Riely, Gregory J.
CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2209 - 2215
[40] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Arnold Lee
Targeted Oncology, 2022, 17 : 727 - 733

← 1 2 3 4 5 →